Universal Beteiligungs und Servicegesellschaft mbH Takes $11.39 Million Position in DaVita Inc. (NYSE:DVA)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in DaVita Inc. (NYSE:DVA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 76,134 shares of the company's stock, valued at approximately $11,386,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.10% of DaVita at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new stake in shares of DaVita during the fourth quarter worth approximately $41,000. Coppell Advisory Solutions LLC increased its holdings in shares of DaVita by 50.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after purchasing an additional 100 shares during the period. Canada Post Corp Registered Pension Plan purchased a new position in DaVita during the 4th quarter worth $55,000. Venturi Wealth Management LLC lifted its position in DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after purchasing an additional 152 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of DaVita by 39.7% in the 4th quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after buying an additional 131 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on DVA. Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research report on Friday, February 21st. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Truist Financial decreased their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday, May 19th. Finally, Barclays lifted their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $164.50.

DaVita Stock Performance

DaVita stock traded up $1.36 during midday trading on Tuesday, reaching $135.77. 995,358 shares of the company's stock were exchanged, compared to its average volume of 873,995. DaVita Inc. has a 52 week low of $131.76 and a 52 week high of $179.60. The stock's 50-day simple moving average is $143.76 and its 200 day simple moving average is $152.63. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The firm has a market cap of $10.25 billion, a price-to-earnings ratio of 12.64, a P/E/G ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.25. The firm had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The company's quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.26 earnings per share. On average, analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.